Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 1, 2006, Pages 107-116

  Eder Jr , Joseph P ^a,b   Ryan, David P ^c   Appleman, Leonard ^a,b   Zhu, Andrew X ^c   Puchalski, Thomas ^c   He, Xiaoying ^c   Sonnichsen, Daryl S ^d   Cooper, Michael ^d   Wright, John ^e   Clark, Jeffrey W ^c   Supko, Jeffrey G ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemotherapy; Human; Pharmacodynamics; Pharmacokinetics

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; FARNESYL TRANS TRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ADULT; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BLADDER CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INFUSION; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LETHARGY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PARAGANGLIOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SARCOMA; SMALL INTESTINE CARCINOMA; SOLID TUMOR; THROMBOCYTOPENIA; UREMIA; VESTIBULAR DISORDER;

ADULT; BENZODIAZEPINES; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; TIME FACTORS;

EID: 33645969539     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0134-0     Document Type: Article

References (16)

1. Midgley RS, Kerr DJ (2002) RAS as a target in cancer therapy. Crit Rev Oncol Hematol 44:109-120
2. Adjei AA (2001) Blocking oncogenic RAS signaling in cancer therapy. J Natl Cancer Inst 93:1062-1074
3. Cohen LH, Pieterman E, van Leeuwen RE et al (2000) Inhibitors of prenylation of RAS and other G-proteins and their applications as therapeutics. Biochem Pharmacol 60:1061-1068
4. Rose WC, Lee FY, Fairchild CR et al (2001) Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res 61:7507-7517
5. Ryan DP, Eder JP Jr, Puchalski T et al (2004) Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. Clin Cancer Res 10:2222-2230
6. Simon R, Freidlin B, Rubinstein L et al (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147
7. Gabrielsson J, Weiner D (1994) Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Swedish Pharmaceutical Press, Stockholm
8. Mizuta E, Tsubotani A (1985) Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull 33:1620-1632
9. Lacey LF, Keene ON, Pritchard JF et al (1997) Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat 7:171-178
10. Miller RG (1974) The jackknife - a review. Biometrika 61:1-15
11. Hahn WC, Counter CM, Lundberg AS et al (2000) Creation of human tumor cells with defined genetic elements. Nature 400:464-468
12. Chin L, Tam A, Pomerantz J et al (2000) Essential role for oncogenic RAS in tumour maintenance. Nature 400:468-472
13. Sebti SM, Adjei AA (2004) Farnesyl transferase inhibitors. Sem Oncol 31(Suppl 1):28-39
14. Hunt JT, Ding CZ, Batorsky R et al (2000) Discovery of (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2- thienysulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem 43:3587-3595
15. Sebti SM, Der CJ (2003) Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3:945-951
16. Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H (2005) Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 23(12):2805-2812